Healthcare investment spans venture capital (VC, primarily investing in early-to-mid stage companies) and private equity (PE, primarily investing in mature companies). Active China healthcare-focused funds: Lilly Asia Ventures (LAV), Qiming Venture Partners, Sequoia China Healthcare, Hillhouse Capital Healthcare, Northern Light Venture Capital Healthcare. Foreign presence: OrbiMed, Sofinnova, and other life science-focused offshore institutions are continuously increasing China market exposure.
## Core Framework for Healthcare Investment Analysis
**Clinical value assessment**: the starting point of any healthcare investment is evaluating a product’s/technology’s genuine clinical value. Core questions: what Unmet Medical Need does this product address? What is the Standard of Care? Is the new product’s advantage higher efficacy, better safety, lower cost, or more convenient administration route? What is the clinical evidence level (RCT vs. observational study vs. case reports)?
**Regulatory pathway analysis**: innovative drug/device regulatory approval pathways directly determine commercialization timelines. China’s NMPA innovative drug accelerated review channels (Priority Review, Breakthrough Therapy), and US FDA Fast Track/Breakthrough Therapy/Accelerated Approval applicability analysis — medical background provides a natural advantage in understanding indication selection and clinical trial design.
**Market size estimation**: patient count (incidence × treatment-seeking rate × treatment rate) × unit price = potential market opportunity. Medical background enables more accurate estimation of treatment-seeking and treatment rates (many junior investors err by equating incidence directly with potential market).
**Competitive landscape analysis**: comparable products (Me-too vs. Best-in-class vs. First-in-class), patent protection periods, entry barriers (technology, qualification, channel barriers).
## Transition Path and Entry Recommendations
**Direct investment entry**: science/medical PhD background → directly apply for VC investment associate/research analyst positions (primarily industry research and project due diligence), starting salary typically RMB 300,000-500,000/year. **Build industry experience first**: clinical → pharma (Medical Affairs/Clinical Research) 2-3 years → apply for VC Research role, higher success rate. **MBA transition**: some achieve transitions via top MBAs’ finance/investment programs (but high cost and long timeline).
See [Medical Career Pivot Overview](https://sunqi.org/medical-career-pivot-overview-en/).
